Cargando…

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

BACKGROUND: Alternative endpoints to overall survival (OS) are frequently used to assess treatment efficacy in randomized controlled trials (RCT). Their properties in terms of surrogate outcomes for OS need to be assessed. We evaluated the surrogate properties of progression-free survival (PFS), tim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savina, Marion, Litière, Saskia, Italiano, Antoine, Burzykowski, Tomasz, Bonnetain, Franck, Gourgou, Sophie, Rondeau, Virginie, Blay, Jean-Yves, Cousin, Sophie, Duffaud, Florence, Gelderblom, Hans, Gronchi, Alessandro, Judson, Ian, Le Cesne, Axel, Lorigan, Paul, Maurel, Joan, van der Graaf, Winette, Verweij, Jaap, Mathoulin-Pélissier, Simone, Bellera, Carine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195375/ https://www.ncbi.nlm.nih.gov/pubmed/30349653 http://dx.doi.org/10.18632/oncotarget.26166

Ejemplares similares

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial
por: Branchoux, S., et al.
Publicado: (2021)

PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)
por: Grellety, Thomas, et al.
Publicado: (2016)

Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study
por: Verschoor, Arie Jan, et al.
Publicado: (2020)

Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database
por: Kantidakis, Georgios, et al.
Publicado: (2022)

Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial
por: Soubeyran, Pierre, et al.
Publicado: (2016)

Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting
por: Belaroussi, Yaniss, et al.
Publicado: (2023)

Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial
por: Italiano, Antoine, et al.
Publicado: (2018)

Imaging endpoints for clinical trial use: a RECIST perspective
por: Litière, Saskia, et al.
Publicado: (2022)

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
por: Savina, Marion, et al.
Publicado: (2017)

Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study
por: Anota, Amélie, et al.
Publicado: (2014)

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison
por: Penel, Nicolas, et al.
Publicado: (2023)

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
por: Cousin, Sophie, et al.
Publicado: (2022)

Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades
por: Toulmonde, Maud, et al.
Publicado: (2023)

Suivi de la réponse sérologique au virus SARS-CoV-2 chez des professionnels de santé d'un centre de lutte contre le cancer dans un contexte de pandémie de COVID19 (PRO-SERO-COV)
por: Cantarel, C., et al.
Publicado: (2022)

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists
por: Methy, Nicolas, et al.
Publicado: (2010)

Radiofrequency ablation of stage IA non–small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial
por: Palussière, J., et al.
Publicado: (2018)

Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer
por: Bellera, Carine A, et al.
Publicado: (2010)

Comment on “Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long-Course Chemoradiotherapy and Surgery: A Five-Year Follow-Up of the RAPIDO Trial”: The RAPIDO Trial Does Not Achieve Its Primary Endpoint
por: Riou, Olivier, et al.
Publicado: (2023)

Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
por: Frezza, Anna Maria, et al.
Publicado: (2014)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)

One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study
por: Richez, Brice, et al.
Publicado: (2023)

Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death
por: Rondeau, Virginie, et al.
Publicado: (2010)

Recent advances in managing gastrointestinal stromal tumor
por: Duffaud, Florence, et al.
Publicado: (2017)

Breast cancer care compared with clinical Guidelines: an observational study in France
por: Lebeau, Marie, et al.
Publicado: (2011)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

From rare to well-done: importance of rare tumors in cancer therapeutic advances
por: Duffaud, Florence, et al.
Publicado: (2019)

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
por: Penel, N, et al.
Publicado: (2011)

Survival analysis with correlated endpoints: joint frailty-copula models
por: Emura, Takeshi, et al.
Publicado: (2019)

How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials
por: Sofeu, Casimir Ledoux, et al.
Publicado: (2020)

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol
por: Lacourt, Aude, et al.
Publicado: (2019)

Validation of death prediction after breast cancer relapses using joint models
por: Mauguen, Audrey, et al.
Publicado: (2015)

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
por: Courtinard, Coralie, et al.
Publicado: (2023)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

One-Year Mortality in Older Patients with Cancer: Development and External Validation of an MNA-Based Prognostic Score
por: Bourdel-Marchasson, Isabelle, et al.
Publicado: (2016)

Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma: COCHISE phase II clinical trial
por: Evrard, Serge, et al.
Publicado: (2019)

Health-related quality of life as an endpoint in oncology phase I trials: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_736jns55773d3l8igtn067qo9d